

# 1 **Single cell transcriptome atlas of immune cells in human small** 2 **intestine and in celiac disease**

3  
4 Nader Atlasy<sup>1,a,4</sup>, Anna Bujko<sup>2,4</sup>, Peter B Brazda<sup>1,a</sup>, Eva Janssen-Megens<sup>1,a</sup>, Espen S.  
5 Bækkevold<sup>2</sup>, Jørgen Jahnsen<sup>3</sup>, Frode L. Jahnsen<sup>2</sup>, Hendrik G. Stunnenberg<sup>1,a,\*</sup>

6  
7  
8 <sup>1</sup>Department of Molecular Biology, Science Faculty, Radboud University, Nijmegen, The  
9 Netherlands.

10 <sup>2</sup> Department of Pathology, University of Oslo and Oslo University Hospital, Rikshospitalet,  
11 Oslo, Norway

12 <sup>3</sup> Department of Gastroenterology, Akershus University Hospital and University of Oslo,  
13 Oslo, Norway.

14  
15 <sup>a</sup>current address: Princess Maxima Centre for Pediatric Oncology, Heidelberglaan 25, 3584  
16 CS Utrecht

17  
18  
19 <sup>4</sup>These authors contributed equally to this study

20  
21  
22 \* Corresponding author: [h.stunnenberg@ncmls.ru.nl](mailto:h.stunnenberg@ncmls.ru.nl)

23  
24  
25  
26 **Celiac disease (CeD) is an autoimmune disorder in which ingestion of dietary gluten**  
27 **triggers an immune reaction in the small intestine<sup>1,2</sup>. The CeD lesion is characterized by**  
28 **crypt hyperplasia, villous atrophy and chronic inflammation with accumulation of**  
29 **leukocytes both in the lamina propria (LP) and in the epithelium<sup>3</sup>, which eventually**  
30 **leads to destruction of the intestinal epithelium<sup>1</sup> and subsequent digestive complications**  
31 **and higher risk of non-hodgkin lymphoma<sup>4</sup>. A lifetime gluten-free diet is currently the**  
32 **only available treatment<sup>5</sup>. Gluten-specific LP CD4 T cells and cytotoxic intraepithelial**  
33 **CD8+ T cells are thought to be central in disease pathology<sup>1,6-8</sup>, however, CeD is a**  
34 **complex immune-mediated disorder and to date the findings are mostly based on**  
35 **analysis of heterogeneous cell populations and on animal models. Here, we**  
36 **comprehensively explore the cellular heterogeneity of CD45+ immune cells in human**  
37 **small intestine using index-sorting single-cell RNA-sequencing<sup>9,10</sup>. We find that myeloid**

38 **and mast cell transcriptomes are reshaped in CeD. We observe extensive changes in the**  
39 **proportion and transcriptomes of CD4+ and CD8+ T cells and define a CD3zeta**  
40 **expressing NK-T-like cell population present in the control LP and epithelial layers that**  
41 **is absent and replaced in CeD. Our findings show that the immune landscape is**  
42 **dramatically changed in active CeD which provide new insights and considerably**  
43 **extend the current knowledge of CeD immunopathology.**

44  
45 To assess the changes in the immune cell landscape of the small intestine in CeD, we  
46 isolated CD45<sup>+</sup> immune cells from LP and the epithelial layer of duodenal biopsies obtained  
47 from newly diagnosed CeD patients and from individuals with normal histology (controls)  
48 (Fig. 1a and Supplementary Table 1). In line with previous studies<sup>11,12</sup>, analysis of the  
49 markers used for index sorting shows that CeD harbors increased numbers of CD45+ cells in  
50 LP and a higher fraction of CD3+ intraepithelial lymphocytes (IELs) as compared to controls  
51 (Extended Data Fig. 1a, b). A modified SORT-seq<sup>10</sup> single-cell RNA-seq protocol and  
52 application of quality control cut offs yielded ~4,000 single cells with high quality RNA  
53 profiles (Fig. 1a and Extended Data Fig. 1c-e). t-Distributed Stochastic Neighbor Embedding  
54 (t-SNE) analysis revealed five major cell compartments that, based on typical lineage  
55 markers (assessed by protein and/or mRNA), were annotated as T-cells (CD3), plasma cells  
56 (PCs) (CD19 and *SDC1* (CD138)), myeloid cells (CD14, CD11c and HLA-DR), mast cells  
57 (MC) (*KIT*) and B cells (*MS4A1* (CD20)) (Fig. 1b-d). Cell size and granularity are in line  
58 with the classical phenotype of the cells (Fig. 1e). The tSNE clusters were formed by  
59 contribution from all donors with no considerable donor batch effect (Extended Data Fig. 1f).

60 We applied the Wilcoxon rank sum test ('Seurat' pipeline<sup>13</sup>) to identify cell type-  
61 specific transcripts distinguishing each cell population (Fig 1f and Supplementary Table 2).  
62 We identified 181 genes differentially expressed in the T-cell compartment with *IL7R*,  
63 *GZMA*, *RORA* amongst the top genes. For PCs, 104 genes largely consisting of  
64 immunoglobulin related genes such as *IGLC2*, *IGLC3*, and *IGHA1*. We found 245 marker  
65 genes distinguishing myeloid cells with *SELENOP*, *SLC40A1*, *HLA-DRA* and *CD74* among  
66 the top genes. MC analysis yielded 229 genes with the top ranked genes being *HPGD*,  
67 *LAPTM4A*, *VIM* and *LMO4*. We could identify in total 98 genes as B cell markers with *CR2*,  
68 *RALGPS2* and *FCRL2* as top ranked genes (Fig. 1f). CeD and control cells populate the same  
69 major cell compartments but a different pattern within the MC, myeloid and T cell  
70 compartments was observed. Virtually all CeD and control IELs clustered with the T-cell  
71 compartment (Fig. 1g).

72 tSNE analysis of the MC compartment revealed 4 clusters (C0-C3). C1 is common to  
73 controls and CeD, whereas C2 and C3 consist mostly of control and CeD cells, respectively  
74 (Figs. 2a, b). MCs from each donor contributed to these three clusters except for C0, which is  
75 donor-specific and was excluded from the subsequent analysis (Extended Data Fig. 2a).  
76 Cluster C3 cells, enriched in CeD, were smaller and less granular (Fig. 2c). The three  
77 clusters differ in their expression levels of *C20orf194* and *FKBP11* that are high in the  
78 common cluster C1, whereas *REG1A* and *HLA-DRB1* are high in the control cell cluster C3  
79 and low in the CeD cluster C3 (Fig. 2d and Supplementary Table 3).

80 tSNE analysis of the myeloid compartment revealed seven clusters (C0-C6) (Fig. 2e).  
81 Clusters C0, C2, and C4 express higher levels of CD163 and lower levels of CD11c (Fig 2e,  
82 g). C2 and C4 differentially express typical macrophage genes<sup>14</sup> (Fig. 2h and Supplementary  
83 Table 3) reminiscent of CD11c- mature macrophages (Mf) which are noticeably  
84 underrepresented in CeD<sup>15</sup> (Fig. 2f and Extended Data Fig. 2b, c). Clusters C1 and C3  
85 express higher levels of ITGAX (CD11c) and FCER1A reminiscent of immature Mf and of  
86 dendritic cells (DC)<sup>16</sup> (Fig. 2e, g). CD11c-high cells were ordered from C1 to C3 and C6 cells  
87 with C3 cells differentially expressing *SLC38A1*, *PLAC8*, *SERPINB9*, *PPA1* and *FCER1A*  
88 and C6 cells expressing *CLEC10A*, a marker associated with cDC2<sup>17</sup> (Fig. 2h). Pseudotime  
89 analysis revealed two trajectories originating from cluster C5 and diverging into a Mf and a  
90 DC path that correspond to CD11c-low and CD11c-high cells, respectively (Fig. 2i). C6 cells  
91 expressing *CLEC10A* are located between the two trajectories suggesting that this cluster  
92 may originate from both the Mf and the DC pathway<sup>16</sup>. C5 cells differentially express  
93 *HELLPAR*, *FBXO22* and *PRRG3* (Fig. 2h). Note that the fluorescent antibody panel used in  
94 the index sorting cannot distinguish C5 cells from the other myeloid cells (Extended Data  
95 Fig. 2d, e). Using linear modeling and Bayesian statistics, we identified *MYBL1* as a highly  
96 expressed transcription factor (TF) in the shared origin of Mf and DC (C5) with *ZEB1*, *IRF8*  
97 and *YBX1* as the potential driver TFs of the MF path and *MAF* of the DC path (Fig. 2i and  
98 Supplementary Table 4).

99 Focusing on the humeral branch of the adaptive immune system, tSNE analysis  
100 identified a small cluster of B cells (C2) and two prominent clusters (C0 and C1) of PCs (Fig.  
101 3a). FACS analysis showed that CD19+ PCs are significantly increased in CeD (Extended  
102 Data Fig. 3a). Based on transcriptome analysis, we noticed that B cells and PCs are rather  
103 equally distributed across the clusters in CeD and control samples (Fig. 3b and Extended  
104 Data Fig. 3b, c). Beside subtle differences in immunoglobulin genes, no major difference  
105 between the two PC clusters could be detected in mRNA, CD19 protein expression and cell  
106 size and granularity (Extended Data Fig. 3d-f and Supplementary Table 5). Pseudotime  
107 analysis revealed B cells at the beginning of the path and the two PCs clusters largely  
108 intermingled along the trajectory (Fig. 3c). Using our linear modeling approach, we identified  
109 1597 and 1210 genes that are gradually up- or down-regulated (Supplementary Table 6). The  
110 TFs *ETS1*, *BCL11A*, *REL*, and *IRF8* are found to be highly expressed in B cells and their  
111 expression is downregulated in PCs. *MEIS2* and *RUNX1* appear to be transiently upregulated  
112 (bin 3) along the pseudotime path whereas *XBPI*, *CREB3L2*, *SUB1* and *PRDM1* are among  
113 the highest expressed TFs in fully differentiated PCs (Fig. 3d and Supplementary Table 6).

114 tSNE analysis of the T-cell compartment (Fig. 1b) yielded three clusters of CD4<sup>+</sup> T  
115 cells (C0, C2 and C4) and four clusters of CD8<sup>+</sup> T cells (C1, C3, C6 and C7) (Fig. 4a and  
116 Extended Data Fig. 4a). Three clusters (C5, C8 and C9), that co-cluster with the T-cell  
117 compartment when analyzing all CD45<sup>+</sup> cells (Fig. 1), turn out to be distinct and are CD4<sup>-</sup>  
118 /CD8<sup>-</sup> at mRNA levels and express no or very low levels of CD3 protein (Fig. 4a-c and  
119 Extended Data Fig. 4c). Expression of the canonical *GZMB*<sup>18</sup> amongst 29 other known and  
120 novel genes, identified cluster C8 as natural killer (NK) cells (Fig. 4e and Supplementary  
121 Table 7). The NK cells are mainly present in the LP and more abundant in CeD than controls  
122 (Fig. 4 d, g). Cells of cluster C9 were less present in CeD and identified as innate lymphoid  
123 cells class 3 (ILC3) based on their expression of *PCDH9*, *KIT*, *ALDOC*, *AHR* and *RUNX2*  
124 genes as previously reported<sup>19</sup> (Figs. 4a, d, e and Supplementary Table 7).

125 Strikingly, the CD4<sup>+</sup> T cells in CeD are different from controls. While control cells  
126 dominate cluster C0 expressing among other genes *IL7R*, *ADAM19*, *TNFSF13*, more than  
127 85% of cells in C2 are from CeD (Fig. 4d). C2 cells express genes including *TBC1D4*, *MAF*,  
128 *BIRC3*, *PHTF2*, *TFRC*, *TIGIT*, *IL32*, *FOXO1*, *GBP5*, *STAT1*, and *IL6R*; several of these are  
129 known to be expressed in both activated and regulatory T cells<sup>20-22</sup> (Fig. 4e and

130 Supplementary Table 7). Gene ontology analysis showed that these cells are significantly  
131 enriched for signaling pathways including ‘Cytokine Signaling in Immune system’, ‘NOD-  
132 like receptor signaling pathway’ and ‘Signaling by Interleukins’ (Supplementary Table 7).  
133 Pseudotime analysis on C2 cells revealed 94 genes that are upregulated along the trajectory  
134 with *GFII* and *MEDI* as the highest expressed TFs in the end of the path (Fig. 4f). *GFII* and  
135 *MEDI* have been shown to regulate T cell activation and NKT cell development,  
136 respectively<sup>23,24</sup>. C4 cells are equally present in CeD and controls and express genes  
137 including *INPP4B*, *ANK3*, *FOXP1* and *AHNAK* (Figs. 4d, e).

138 CD8<sup>+</sup> T cells in CeD clusters are also very differently from controls. Clusters C1 and  
139 C3 contain 75% and 95% CeD cells, respectively (Fig. 4d). Importantly, the clusters contain  
140 the vast majority of both LP and intraepithelial CD8<sup>+</sup> T cells (Fig. 4h). C1 cells differentially  
141 express *KLRC2* and *KLRD1* both NK markers known to be involved in the cytotoxic activity  
142 of CD8 IELs in CeD<sup>25,26</sup>. They also express *TRGC2* suggesting that gamma delta T cells are  
143 within this cluster. C3 cells express *ITGAE* and *CD101*, marker genes for resident memory T  
144 cells<sup>27</sup>, and *CCL5*, *HLA-DP* and *ENTPDI* (CD39), all expressed on activated CD8<sup>+</sup> T cells  
145 (Fig. 4e and Supplementary Table 7). Interestingly, CD39 was recently shown to be a marker  
146 for tumor-specific CD8 T cells<sup>28</sup>. Control CD8<sup>+</sup> T cells mainly contribute to cluster C6 and  
147 highly express *LRP12* and *GPR155*. Cluster C7 contains slightly more CeD cells that  
148 differentially express *GZMK* and *KLRG1* suggesting they are recently recruited memory  
149 CD8<sup>+</sup> T cells<sup>29</sup> (Figs. 4a, d, e and Extended Data Fig. 4c and Supplementary Table 7).  
150 Pseudotime analysis of clusters C1 and C3 revealed a developmental trajectory in which it  
151 appears that C1 cells progress towards C3 cells. Applying our linear modeling, we found that  
152 *IKZF2* is the potential driving TF expressed in C1 cells and *E2F3*, *RUNX2*, and *TCF3* among  
153 others in C3 (Fig. 4f and Supplementary Table 8).

154 Our analysis reveals that IELs in control individuals consist of two distinct populations:  
155 CD3low and CD3high cells. The CD3high IELs are mostly CD8<sup>+</sup> T cells (Figs. 4g). The  
156 CD3low IELs are bigger in size and more granular as compared to the other cells in the T-cell  
157 compartment (Extended Data Fig. 4b) and are mainly CD4low/CD8low/ CD247 high (CD3  
158 zeta) cells (cluster C5, Figs. 4a, b, g and Extended Data Fig. 4c). We classify cluster C5 cells  
159 as ‘NK-T’ as they express classical NK as well as T cell genes such as *TRDC*, *GZMA*,  
160 *FCER1G*, *CDH17*, *CD69*, *TYROBP* and *ID2* (Fig. 4e and Supplementary Table 7). This  
161 transcriptome profile is very similar to that described for natural IELs in mice<sup>30</sup>. The CD3low  
162 cells in C5 are not exclusively intraepithelial as ~25% of the cells are located in the LP  
163 (Extended Data Fig. 4d). Moreover, C5 cells are remarkably underrepresented or absent in  
164 CeD (Figs. 4d, h and Extended Data Fig. 4d). Together, we find that the majority of CD8<sup>+</sup> T  
165 cells in both LP and epithelium express an activated phenotype in CeD compared to controls,  
166 suggesting that CD8<sup>+</sup> T cells in both compartments are actively involved in CeD pathology.

167 In conclusion, we find a dramatic change of the immune cell landscape in the active  
168 CeD lesion. The number of CD3<sup>+</sup> T cells is increased and the majority of CD4<sup>+</sup> and CD8<sup>+</sup> T  
169 cells are transcriptionally very different from their control counterparts. At the same time  
170 mature Mf with regulatory properties are greatly reduced and NK-T IELs are virtually absent  
171 in CeD. Our atlas thus provides an important framework to increase our knowledge about this  
172 complex immune-mediated disease.

173

174

175

176

177

References:

- 178 1 Jabri, B. & Sollid, L. M. Tissue-mediated control of immunopathology in coeliac  
179 disease. *Nat Rev Immunol* **9**, 858-870, doi:10.1038/nri2670 (2009).
- 180 2 Shan, L. *et al.* Structural basis for gluten intolerance in celiac sprue. *Science* **297**,  
181 2275-2279, doi:10.1126/science.1074129 (2002).
- 182 3 Ludvigsson, J. F. *et al.* The Oslo definitions for coeliac disease and related terms. *Gut*  
183 **62**, 43-52, doi:10.1136/gutjnl-2011-301346 (2013).
- 184 4 Illus, T., Kaukinen, K., Virta, L. J., Pukkala, E. & Collin, P. Incidence of malignancies in  
185 diagnosed celiac patients: a population-based estimate. *Am J Gastroenterol* **109**,  
186 1471-1477, doi:10.1038/ajg.2014.194 (2014).
- 187 5 Ludvigsson, J. F. *et al.* Diagnosis and management of adult coeliac disease: guidelines  
188 from the British Society of Gastroenterology. *Gut* **63**, 1210-1228, doi:10.1136/gutjnl-  
189 2013-306578 (2014).
- 190 6 Jabri, B. & Sollid, L. M. T Cells in Celiac Disease. *J Immunol* **198**, 3005-3014,  
191 doi:10.4049/jimmunol.1601693 (2017).
- 192 7 Christophersen, A. *et al.* Distinct phenotype of CD4(+) T cells driving celiac disease  
193 identified in multiple autoimmune conditions. *Nat Med* **25**, 734-737,  
194 doi:10.1038/s41591-019-0403-9 (2019).
- 195 8 Mayassi, T. *et al.* Chronic Inflammation Permanently Reshapes Tissue-Resident  
196 Immunity in Celiac Disease. *Cell* **176**, 967-981 e919, doi:10.1016/j.cell.2018.12.039  
197 (2019).
- 198 9 Hashimshony, T. *et al.* CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq.  
199 *Genome Biol* **17**, 77, doi:10.1186/s13059-016-0938-8 (2016).
- 200 10 Muraro, M. J. *et al.* A Single-Cell Transcriptome Atlas of the Human Pancreas. *Cell*  
201 *Syst* **3**, 385-394 e383, doi:10.1016/j.cels.2016.09.002 (2016).
- 202 11 Halstensen, T. S. & Brandtzaeg, P. Activated T lymphocytes in the celiac lesion: non-  
203 proliferative activation (CD25) of CD4+ alpha/beta cells in the lamina propria but  
204 proliferation (Ki-67) of alpha/beta and gamma/delta cells in the epithelium. *Eur J*  
205 *Immunol* **23**, 505-510, doi:10.1002/eji.1830230231 (1993).
- 206 12 Carroccio, A. *et al.* Duodenal and Rectal Mucosa Inflammation in Patients With Non-  
207 celiac Wheat Sensitivity. *Clin Gastroenterol Hepatol* **17**, 682-690 e683,  
208 doi:10.1016/j.cgh.2018.08.043 (2019).
- 209 13 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell  
210 transcriptomic data across different conditions, technologies, and species. *Nat*  
211 *Biotechnol* **36**, 411-420, doi:10.1038/nbt.4096 (2018).
- 212 14 Bujko, A. *et al.* Transcriptional and functional profiling defines human small intestinal  
213 macrophage subsets. *J Exp Med* **215**, 441-458, doi:10.1084/jem.20170057 (2018).
- 214 15 Beitnes, A. C. *et al.* Density of CD163+ CD11c+ dendritic cells increases and CD103+  
215 dendritic cells decreases in the coeliac lesion. *Scand J Immunol* **74**, 186-194,  
216 doi:10.1111/j.1365-3083.2011.02549.x (2011).
- 217 16 Richter, L. *et al.* Transcriptional profiling reveals monocyte-related macrophages  
218 phenotypically resembling DC in human intestine. *Mucosal Immunol* **11**, 1512-1523,  
219 doi:10.1038/s41385-018-0060-1 (2018).
- 220 17 Heger, L. *et al.* CLEC10A Is a Specific Marker for Human CD1c(+) Dendritic Cells and  
221 Enhances Their Toll-Like Receptor 7/8-Induced Cytokine Secretion. *Front Immunol* **9**,  
222 744, doi:10.3389/fimmu.2018.00744 (2018).



- 223 18 Crinier, A. *et al.* High-Dimensional Single-Cell Analysis Identifies Organ-Specific  
224 Signatures and Conserved NK Cell Subsets in Humans and Mice. *Immunity* **49**, 971-  
225 986 e975, doi:10.1016/j.immuni.2018.09.009 (2018).
- 226 19 Yudanin, N. A. *et al.* Spatial and Temporal Mapping of Human Innate Lymphoid Cells  
227 Reveals Elements of Tissue Specificity. *Immunity* **50**, 505-519 e504,  
228 doi:10.1016/j.immuni.2019.01.012 (2019).
- 229 20 Newton, R. H. *et al.* Maintenance of CD4 T cell fitness through regulation of Foxo1.  
230 *Nat Immunol* **19**, 838-848, doi:10.1038/s41590-018-0157-4 (2018).
- 231 21 Miragaia, R. J. *et al.* Single-Cell Transcriptomics of Regulatory T Cells Reveals  
232 Trajectories of Tissue Adaptation. *Immunity* **50**, 493-504 e497,  
233 doi:10.1016/j.immuni.2019.01.001 (2019).
- 234 22 Solomon, B. L. & Garrido-Laguna, I. TIGIT: a novel immunotherapy target moving  
235 from bench to bedside. *Cancer Immunol Immunother* **67**, 1659-1667,  
236 doi:10.1007/s00262-018-2246-5 (2018).
- 237 23 Yue, X., Izcue, A. & Borggrefe, T. Essential role of Mediator subunit Med1 in invariant  
238 natural killer T-cell development. *Proc Natl Acad Sci U S A* **108**, 17105-17110,  
239 doi:10.1073/pnas.1109095108 (2011).
- 240 24 Suzuki, J. *et al.* Gfi1, a transcriptional repressor, inhibits the induction of the T helper  
241 type 1 programme in activated CD4 T cells. *Immunology* **147**, 476-487,  
242 doi:10.1111/imm.12580 (2016).
- 243 25 Meresse, B. *et al.* Reprogramming of CTLs into natural killer-like cells in celiac  
244 disease. *J Exp Med* **203**, 1343-1355, doi:10.1084/jem.20060028 (2006).
- 245 26 Jabri, B. *et al.* Selective expansion of intraepithelial lymphocytes expressing the HLA-  
246 E-specific natural killer receptor CD94 in celiac disease. *Gastroenterology* **118**, 867-  
247 879, doi:10.1016/s0016-5085(00)70173-9 (2000).
- 248 27 Snyder, M. E. *et al.* Generation and persistence of human tissue-resident memory T  
249 cells in lung transplantation. *Sci Immunol* **4**, doi:10.1126/sciimmunol.aav5581 (2019).
- 250 28 Simoni, Y. *et al.* Bystander CD8(+) T cells are abundant and phenotypically distinct in  
251 human tumour infiltrates. *Nature* **557**, 575-579, doi:10.1038/s41586-018-0130-2  
252 (2018).
- 253 29 Weng, N. P., Araki, Y. & Subedi, K. The molecular basis of the memory T cell  
254 response: differential gene expression and its epigenetic regulation. *Nat Rev*  
255 *Immunol* **12**, 306-315, doi:10.1038/nri3173 (2012).
- 256 30 Cheroutre, H., Lambolez, F. & Mucida, D. The light and dark sides of intestinal  
257 intraepithelial lymphocytes. *Nat Rev Immunol* **11**, 445-456, doi:10.1038/nri3007  
258 (2011).
- 259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270

271 **Acknowledgements**

272 HGS and NA are supported by the Central European University European Research Council  
273 Advanced Grant SysStemCell (339431).

274

275

276

277

278 **Author Contributions**

279 NA, AB, ESB, FLJ and HGS designed the study. NA, EJ-M and PBB set up the experimental  
280 work flow. NA performed the single cell RNAseq experiments, analyzed the single cell  
281 transcriptome data and integrated the flowcytometry data. AB and ESB performed the single  
282 cell isolation, antibody indexing and FACS sorting and analyzed the flowcytometry data. JJ  
283 responsible for patient material. All authors contributed to the writing of the manuscript.  
284 HGS is the corresponding author who supervised the study and contributed in data  
285 interpretations.

286

287

288 **Additional information**

289


290 **Extended data** is available for this study at <http://>

291

292 **Supplementary information** is available for this study at <http://>

293

294




295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305

**Fig. 1 | Single-cell CD45<sup>+</sup> immune cells in human small intestine (hSI) of CeD and control samples.**

**a**, Schematic study design **b**, tSNE cluster plot of hSI CD45<sup>+</sup> cells based on single cell mRNA expressions. **c**, Flowcytometric antibody intensity plots of the canonical markers in the CD45<sup>+</sup> single cells in CeD and normal controls. **d**, Single-cell RNA-seq mRNA expression of selected genes in the tSNE-clusters of the CD45<sup>+</sup> cells. **e**, Flowcytometric analysis scatter and box plots of CD45<sup>+</sup> cells using FSC and SSC read outs. **f**, Heatmap of differentially expressed genes of each cluster (cell type) showing the top ranked genes. **g**, Projection of the Celiac and control derived cells on the tSNE clusters and the IELs in Celiac and control samples.






306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320

**Fig. 2|Single-cell landscape of Mast and myeloid cells in hSI of CeD and control samples.**


**a**, tSNE cluster plot of CD45+ mast cells in CeD and control samples. **b**, Overlay of Celiac and control cells on the mast cells tSNE clusters. **c**, Flowcytometric analysis box plots of the mast cells using FSC and SSC. **d**, Violin plots of selected mast cell cluster marker genes. **e**, tSNE clustering plot of mRNA expressions of CD45+ myeloid cells in Celiac and control samples. **f**, Projection of Celiac and control cells from Intraepithelium and Lamina Propria cells on the myeloid cell tSNE clusters. **g**, Flowcytometric antibody intensity of CD11c, CD14 and HLA-DR proteins in the myeloid cells on the tSNE clusters (top) and mRNA expression patterns of selected genes across the myeloid tSNE clusters (bottom). **h**, Heatmap of differentially expressed genes of myeloid clusters depicting the selected top ranked genes. **i**, Pseudotime analysis plots of the myeloid cells with corresponding 'Macrophage' and 'DC' trajectory scatter plots depicted underneath the top expressed TFs in bins 1 to 5 of the trajectory path (side legends correspond to the myeloid tSNE-clusters involved in each trajectory path).



321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331

**Fig. 3|Single-cell landscape of B and plasma cells in hSI in CeD and control samples.**

**a**, tSNE analysis clustering plot of the B and Plasma cells in Celiac and control using single-cell RNA-seq expression profiles. **b**, Overlay of Celiac and control derived cells from Intraepithelium and LP on on the tSNE-clusters. **c**, Pseudotime analysis plot of B and Plasma cells with projection of the tSNE clusters (top scatter plots) and heatmap of up- and down-regulated genes along the B to Plasma cells trajectory path. **d**, Heatmaps and the top ranked potential 'driving' TFs obtained by the linear modeling that are differentially expressed in each bin of the pseudotime trajectory along the B to Plasma cell paths.



**Fig. 4| Single-cell landscape of T-cell compartment in hSI of CeD and control samples.**

**a**, tSNE clustering plot of the cells in T-cell compartment (as in Figure 2a) using single-cell RNA-seq transcriptome profiles depicting *CD4+*, *CD8+*, ILCs, NK and NK-T cell clusters. **b**, Flowcytometric analysis scatter plot of CD3 protein expression in the T-cell compartment across related tSNE clusters. **c**, Scatter plot of CD3 expression and FSC signals showing CD3high and CD3low cells. **d**, Projection of Celiac and control derived T-cell compartment cells showing the CeD CD8+ enriched (rectangles) and CeD CD4+ enriched (ovals) clusters together with the related proportional bar plots on the tSNE-resulted clusters. **e**, Heatmap of differentially expressed genes among tSNE-clusters showing the top ranked genes for each cluster. **f**, Pseudotime analysis scatter plots of the CD4+ (top panel) and CD8+ (bottom panel) cells depicting the trajectory paths and the related heatmaps of up- and down-regulated genes along each path with the top potential 'driving' TFs present in each bin (bottom axis; five bin segments) along the trajectory. **g**, **h**, Scatter plots of FACS CD3 expression (left) and tSNE cluster distribution (right) of IELs in control samples and in CeD, respectively.

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

## 351 **Extended data**

352

### 353 **Methods**

#### 354 **Tissue samples**

355 Duodenal biopsies were obtained during routine endoscopy at Akershus University Hospital  
356 from patients referred due to suspicion of celiac disease. Diagnosis of celiac disease followed  
357 standard procedure (Ludvigsson et al., 2014). 8 (all females, median age 29.7) patients with  
358 confirmed untreated celiac disease (Marsh score 3A-3C) and 6 (5 females, median age 35.8)  
359 confirmed non-celiac controls have been enrolled in the study. See Table 1 for the list of  
360 patients and their clinical information. Biopsies have been placed immediately in ice-cold  
361 buffered saline, transported on ice, and processed within 4h. The study was approved by the  
362 Norwegian Regional Committee for Medical Research ethics (REK 2012/341), and all  
363 patients gave written informed consent.

#### 364 **Preparation of single cells suspension**

365 To separate the epithelium and intraepithelial lymphocytes biopsies were shaken twice in 6.5  
366 ml of PBS with 2mM EDTA (Sigma-Aldrich), 1% FCS (Sigma-Aldrich) and 1 $\mu$ M  
367 flavopirydol (Sigma-Aldrich) for 10 min at 37°C. Supernatants containing the epithelial  
368 fractions were combined, washed, passed through 100  $\mu$ m cell strainers (Miltenyi Biotec),  
369 washed again and kept on ice until staining. Epithelium-free mucosa was minced and  
370 incubated with stirring in 2.5 ml of RPMI1640 (Lonza) containing 10% FCS, 1% Pen/Strep  
371 (Lonza), 1 $\mu$ M flavopirydol, 0.25 mg/ml Liberase TL (Roche) and 20 U/ml DNase I (Sigma)  
372 for 40 min at 37°C. Halfway through the incubation the samples were triturated using 1 ml  
373 pipette to facilitate complete digestion. Digested cell suspension was passed through 100  $\mu$ m  
374 cell strainer and washed twice.

#### 375 **FACS sorting**

376 Cells were stained with a combination of fluorescent antibodies in FACS buffer for 20 min  
377 on ice, washed twice, and filtered through 100  $\mu$ m nylon filter mesh before sorting. Both  
378 lamina propria and epithelial fractions were stained with: FcR Blocking Reagent (Miltenyi  
379 Biotec), CD45-APC-H7 (2D1, BD Biosciences), CD3-APC (OKT3, Biolegend), CD19-  
380 BV421 (HIB19, Biolegend), HLA-DR-PerCP-Cy5.5 (L234, Biolegend), CD14-PE-Cy7  
381 (HCD14, Biolegend), CD11c-PE (S-HCL-3, BD Biosciences). EpCAM-FITC (Ber-EP4,  
382 Dako) was added to the epithelial fraction to label epithelial cells. In some samples CD27-  
383 BV605 (O323, Biolegend) and CD103-BV605 (Ber-ACT8, Biolegend) were added to the  
384 lamina propria and epithelium fraction, respectively. Dead cells were stained and excluded  
385 using To-Pro-1 (Molecular Probes). Doublets were identified and excluded based on scatter  
386 parameters in forward scatter area versus height (FSC-A/FSC-H) and side scatter area versus  
387 width (SSC-A/SSC-W) plots. Cells of interest (single live CD45+, or single live  
388 CD45+(CD27-)CD3-CD19- to enrich for myeloid cells) were index sorted into Bio-Rad Hard  
389 Shell 384 well microplates (Bio-Rad) containing well specific primers (100 nl, 0.75pmol/ul)  
390 and 5 ul mineral oil (Sigma-Aldrich) on top using FACS Aria Iiu or FACS Aria III with  
391 FACS Diva software version 8 (BD Biosciences). After sorting plates were sealed, labelled,  
392 span down for 10 min at 2000g, snap frozen on dry ice and kept at -80°C until used. In  
393 addition, a minimum of 10<sup>5</sup> total events from each sample were recorded and exported with  
394 index sort files for analysis in FlowJo software.

#### 395 **scRNA-seq modified SORT-seq**

396 In order to obtain the transcriptome of immune cells of small intestine in Celiac and normal  
397 controls, we used the SORTseq protocol (Muraro *et al.* 2016) which itself is a derivatives of  
398 original CEL-Seq2 protocol (Hashimshony, T. et al 2016) and applied some modifications to  
399 the original protocols. In brief, single immune cells were first indexed with canonical markers



400 of interest using the previously described antibodies and then sorted in 384-well PCR plates  
401 (BioRad). The plates were already primed with unique primers per each well in which each  
402 primer has a unique cell barcode with UMI incorporated to tag each RNA molecule in the  
403 cell. Sorted plates then were kept frozen at -80 °C before proceeding to cDNA synthesis. The  
404 frozen plates were shortly centrifuged at 1200 RPM for 1 minute at 4 °C and incubated in the  
405 PCR machine at 60 °C for 2 minutes to break the cells and release the RNA.

406 We used micro-dispenser machine, Nanodrop II (BioNex) to dispense all the reagents in the  
407 next steps of library preparation. After cell breakage, 100 nl lysis buffer contains RNase  
408 inhibitor (RNasin PLUS promega), Triton X100, ERCC spike in control RNAs 1:50,000  
409 diluted (Ambion) were added to each well, short spun at 1200 RPM for 1 minute and  
410 incubated in the PCR machine at 65 °C for 2 minutes and then immediately put on ice for 5  
411 minutes.

412 Then first 150 nl cDNA reaction mix contains first strand cDNA synthesis buffer  
413 (Invitrogen), SuperscriptII reverse transcriptase (Invitrogen), 0.1M DTT and RNasein PLUS  
414 (promega) was added to each well of the plate and the plates were spun at 1200 RPM at 4  
415 °C for 1 minute and placed in PCR machine at 42 °C for 1 hour followed by 10 minutes  
416 enzyme deactivation at 70 °C and immediately placed on ice.

417 Then, the 500 nl second strand DNA reaction mix contains second strand cDNA synthesis  
418 buffer (Invitrogen), 10 mM dNTP, E.Coli DNA ligase enzyme (NEB), E.coli DNA  
419 polymerase enzyme (NEB) and RNaseH enzyme (com) was added to each well of the plate  
420 and then plates were spun for 1 minute at 1200 RPM and placed in the PCR machines at  
421 16 °C for 2 hours followed by enzyme deactivation at 70 °C for 10 minutes and then placed  
422 on ice.

423 To remove the excess remainder of the primers in the reaction mix in each well, we used  
424 exonuclease-I enzyme (NEB) and incubated the plates at 37 °C for 20 minutes followed by  
425 enzyme deactivation at 85 °C for 15 minutes and immediately placed the plates on ice.

426 To reduce the DNA loss during the subsequent steps of library preparation, we linearly  
427 amplified the cDNA content of each well using unidirectional linear-PCR using Pfu DNA  
428 polymerase enzyme (Promega), forward primer against the common sequence of the T7-P5  
429 part of the original oligo-dT primers and ran the linear-PCR for 15 cycles with 2 minutes  
430 preheating at 95°C, then sequential cycles of 30 seconds at 94°C, 30 seconds at 50°C and 3  
431 minutes at 72°C and ended by incubation at 72°C for 5 minutes and then placed plates on ice.

432 After linear amplification of the DNA content in each well, the reaction solution of all wells  
433 per each plate were pooled together (~ 600 ul) and the DNA was cleaned up using AMPure  
434 XP beads by mixing 100 ul XP beads with 600 ul clean up buffer contains PEG and tween  
435 and adding it to the DNA pool. The DNA-bound beads then washed two times with 80%  
436 ethanol and the DNA was eluted in 22 ul EB buffer.

437 Then the amplified single strand DNA fragments of each pool was second stranded using  
438 second strand DNA synthesis buffer (NEB), first strand cDNA synthesis buffer(NEB), 0.1M  
439 DTT, random hexamer primer mix (Thermo), dNTP mix, E.coli DNA polymerase (NEB) and  
440 E.coli DNA ligase (NEB) in 50 ul reaction volume and incubated for 2 hours at 16°C. Then  
441 the DNA was cleaned up using 2x XP-bead:DNA ratio and eluted in 7 ul water.

442 Then the DNA was amplified and transformed to RNA using in vitro transcription overnight  
443 according to manufacturer's protocol (Ambion Mega-Script IVT kit) at 37°C. The amplified  
444 RNA (aRNA) then was treated with ExoI-rSAP enzymes for 20 minutes at 37°C and  
445 fragmented using Manganese based fragmentation buffer for 1.5 minutes at 94°C followed by  
446 incubation with 0.5M EDTA buffer to stop the fragmentation process. The fragmented aRNA  
447 was subsequently cleaned up using 2x XP-bead:aRNA ratio and eluted in 12 ul water.

448 We used 5 ul of the aRNA and proceeded to next step of library preparation. The cleaned  
449 aRNA was converted to cDNA using 1 ul of random octamer primers that contain part of T7



450 sequence of Illumine library oligos and the reaction mix contains first strand cDNA buffer  
451 (NEB), 0.1M DTT, 10mM dNTPs, RNasein PLUS (Promega) and SuperscriptII reverse  
452 transcriptase enzyme (Invitrogen) was incubated at 25°C for 10 minutes followed by  
453 incubation at 42°C for 1 hour and 70°C for 10 minutes and then placed on ice. Then the final  
454 library was amplified and enriched by 7 cycles of PCR using KAPA hyper prep kit and  
455 adding forward and reverse primers against Illumine T5 and T7 sequences in which the  
456 reverse primer contained unique sequence and added specifically per each sample/library.  
457 The library then was cleaned with 1:1 XP-bead:DNA ratio and eluted in 20 ul elution buffer.  
458 The quantity of the library was measured using KAPA library quantification kit (Roche) and  
459 the quality was checked by using the bioanalyzer machine (Agilent).

#### 460 **scRNA-seq data analysis**

461 Each library obtained from one plate was sequenced for on average 40 million reads using  
462 NextSeq 500 sequencer. The raw FASTQ files (Read2 contains 8nt cell barcode + 8nt UMI;  
463 Read1 contains mRNA sequence) were used as input for the CEL-Seq2 pipeline  
464 (Hashimshony, T. *et al.* 2016) however, incorporating STAR aligner  
465 (<https://github.com/alexdobin/STAR>) to map the sequenced reads against the human genome  
466 HG38 using the default parameters. The uniquely mapped reads then were demultiplexed per  
467 each single cell per library using the known 384 cell barcodes. The demultiplexed, uniquely  
468 mapped reads per each single cell then were counted against the reference genome and PCR  
469 deduplicated using HTSeq-count part of the CEL-Seq2 pipeline and the table of read counts  
470 for all single cells (~12,000 single cells) was built using R environment.

471 To remove the low-quality cells from the dataset, we applied several criteria's. Cells with  
472 MAD of ERCC and mitochondrial counts and library size greater than 3 were removed. Next,  
473 cells with total detected genes less than 400 and more than 4000 were also excluded from the  
474 dataset. We included no-cell and 12x-cell wells during the sorting of the cells in the plates  
475 and used these wells as background and multicell controls for the analysis respectively. Cells  
476 with Pearson correlation greater than  $r > 0.8$  as compared to the multicell controls, were  
477 excluded from the dataset as doublets. We also removed the drop-out genes from the dataset  
478 and also the genes which had expression ratio of background to signal greater than 1. The  
479 dataset of filtered high quality cells (~4000) then was normalized using DESeq package  
480 incorporating the ERCC spike-ins and used for further analysis.

481 Subsequently, we used Seurat v.2 pipeline (Butler *et al.* 2018 ) to identify the possible  
482 clusters of cells and the main cell populations using the Wilcoxon Ranked-sum test with the  
483 default parameters. Then using Seurat, we identified marker genes per each cluster of cells  
484 and used the obtained marker genes to further do the heatmap analysis and the gene ontology  
485 analysis accordingly in R environment using pheatmap and gprofiler packages, respectively.  
486 The tSNE analysis was subsequently performed using the related integrated function within  
487 the Seurat package with the default parameters.

488 To assess any possible trajectory within the cells of interest, we did pseudo-time analysis on  
489 the selected cells using Slingshot algorithm incorporated in the dynverse pipeline  
490 (<https://github.com/dynverse>) and to check for any up-regulation and down-regulation  
491 patterns of genes within the trajectory path, we applied a linear modeling analysis  
492 incorporating a Bayesian statistics using Limma package (Ritchie ME *et al.* 2015 ) with the  
493 default parameters. To identify the possible driving transcription factors (TFs) along the  
494 trajectory path, we divided each of the trajectory paths into 5 bins using the start- and end-  
495 point cells along the pseudotime dominant dimension and applied the linear modeling per  
496 each bin of the trajectory path. Then the TFs with  $FDR < 0.05$  were selected as the potential  
497 driving factors of each bin and per path. The simulation analysis was additionally performed  
498 in some examples to assess the possible difference between clusters of cells that would not  
499 result in a significant cluster markers using Seurat Wilcoxon ranked-sum algorithm and

500 pipeline. In this regard, we randomly selected  $n$  number ( $n=20\%*total\ cells\ of\ the\ cluster$ ) of  
501 cells from each cluster of cells resulted from Seurat pipeline and constructed a mean-based  
502 mini-bulk sample of the related cluster of cells. We accordingly permuted this simulation for  
503 1000 times and then applied the hierarchical clustering on the highly variable genes across  
504 the simulated mini-bulk samples and used the resulted genes for further gene ontology  
505 analysis.

506

#### 507 **Data Availability**


508 The dataset generated during and/or analyzed during the current study are available in the  
509 EGA database under data accession number EGAD00001005127 at [https://ega-](https://ega-archive.org/studies/EGAS00001003751)  
510 [archive.org/studies/EGAS00001003751](https://ega-archive.org/studies/EGAS00001003751)

511

512

513


Extended Data Fig. 1



514  
515 **Extended Data Fig. 1| Single-cell CD45<sup>+</sup> immune cells in human small intestine; Donor**  
516 **contribution and quality control.**

517 **a**, Relative representation of CD45<sup>+</sup> immune cells among all live cells from control (ctrl; n = 6) and CeD (n = 8)  
518 samples. **b**, Relative representation of CD3<sup>+</sup> T cells among all CD45<sup>+</sup> cells from control (ctrl; n = 6) and CeD (n  
519 = 8) samples in the epithelial (left) and LP (right) fraction. **c**, Histogram plot of gene coverage per each single  
520 cell showing the average gene coverage in empty control wells as background (red line) and the applied  
521 thresholds in gene coverage (dashed blue lines). **d**, Histogram plot of Pearson correlation r scores of single cells  
522 with the control multi-cell sorted wells (vertical line showing the cut-off set to r=0,8). **e**, Histogram plot of  
523 background (empty wells) to signal (single cell sorted wells) mRNA expression ratios across all the detected  
524 genes among single cells showing the distribution of the ratios and the applied threshold; genes with  
525 background/signal ratio greater than 1.0 (red line) were removed from the data. **f**, Bar plot of donor  
526 contribution to each cluster of cells obtained from tSNE analysis.  
527

Extended Data Fig. 2




528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538

**Extended Data Fig. 2| Mast and myeloid cells in hSI in CeD and control samples; FACS analysis and donor contribution.**

**a**, Bar plots of donor contribution in each cluster of the cells obtained from the Mast cells tSNE analysis (left) and the related Celiac vs. control contribution to each cluster (right). **b**, Bar plots of donor distribution (left) and Celiac vs. control contribution (right) per each tSNE cluster of the myeloid cells. **c**, The ratio of CD11c<sup>-</sup> macrophages to CD11c<sup>+</sup> macrophages (left) and relative representation of CD11c<sup>-</sup> macrophages (middle left), CD11c<sup>+</sup> macrophages (middle right), and dendritic cells (right) among all CD45<sup>+</sup> LP cells from control (ctrl; n = 6) and CeD (n = 8) samples. **d**, Box plots of cell size and cell granularity measured via flowcytometric analysis on the myeloid cells. **e**, Flowcytometric analysis scatter plots of selected markers in the myeloid cells.

Extended Data Fig. 3



539  
540


**Extended Data Fig. 3| B and plasma cells in hSI in CeD and control samples.**

541 **a**, Relative representation of CD19<sup>+</sup> B cells (left), CD19<sup>+</sup> plasma cells (middle), and CD19<sup>-</sup> plasma cells (right)  
542 among all CD45<sup>+</sup> LP cells from control (ctrl; n = 6) and CeD (n = 8) samples. **b**, Donor contribution bar plot of  
543 B and Plasma cells per each tSNE derived cluster. **c**, Bar plot of Celiac vs. control contribution per each tSNE-  
544 cluster of cells. **d**, Flowcytometric analysis box plots of B and Plasma cells using FSC and SSC read outs. **e**,  
545 Scatter plot of CD19 protein expression among all B and Plasma cells on the tSNE plot using flowcytometric  
546 signal intensities. **f**, Violin plots of the differentially expressed genes between B- and Plasma-cell clusters  
547 resulted from the tSNE analysis depicting the top ranked candidate genes.  
548

549  
550



Extended Data Fig. 4



551  
552  
553  
554  
555  
556  
557  
558  
559  
560

**Extended Data Fig. 4| T-cell compartment in hSI in CeD and control samples.**

**a**, Bar plot of donor distribution per each cluster of cells obtained from tSNE analysis on the T-cell compartment. **b**, Flowcytometric analysis box plots depicting the cell size and cell granularity across all tSNE-clusters of T-cell compartment using FSC and SSC read outs **c**, Scatter plots of mRNA expression of selected genes on the tSNE clusters of T-cell compartment showing the *CD4+* and *CD8+* expressing clusters. **d**, Pie plots of T-cell clusters showing the relative contribution of LP and IE obtained from Celiac and control samples.

561

562